The Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency (EMA) will keep reviewing reports on pericarditis and myocarditis following vaccination with Johnson & Johnson's covid-19 vaccine. PRAC concludes that more data and investigation will be needed in order to assess whether there is a documented connection between cause and effect, according to the Danish Medicines Agency (DMA).
PRAC has further stated that it is closely monitoring thrombosis with thrombocytopenia syndrome in connection with the vaccine, but has no updates on this at the moment.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Zealand Pharma sells shares for over USD 100m
With a 5% discount, the biotech company managed to sell 4,975,000 of its own shares in a direct issuance.
Zealand Pharma CEO: Share sale arms us for partnership negotiations
After a study success with short bowel syndrome treatment candidate, the Danish biotech company raised funding by issuing shares, preparing the company’s CEO, Adam Steensberg, to enter dialogs with a number of potential partners.
Complete company divestment is not part of Zealand Pharma's strategy
After a Nordnet analyst brought up the possibility of the Danish company being an acquisition target for foreign firms, CEO Adam Steensberg has ruled out the notion of a full sale.
Three scientists share chemistry Nobel for cancer improvement technology breakthrough
Danish national Morten Meldal and two colleagues have been awarded the prestigious award for their research into click chemistry, which is used the development of cancer drugs.
Audientes builds on Q2 momentum, maintains guidance
The hearing aid company has sold self-fitting hearing aids for over DKK 2m (USD 266,700) during the third quarter that ended in September.
Nordic Key Account Manager, Hollister & Dansac 
Senior CMC Regulatory Manager 
Pharmacovigilance & Regulatory Officer 
KLIFO is looking for QA Specialist/Senior QA Specialist, GCP and GVP for our Glostrup office 
Product specialist 
Senior/lead consultant at Emendo Engineering 
Upstream Processing CMC Specialist 
Head of department RA/QA/PV, Danmark 
Experienced Medical Device Developer 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
Drug Safety Associate 
Orifarm Healthcare Product Development PMO Director 
Chief Business Officer 
Clinical Project Lead